Skip to content
PeptideTech
Cart
live116 compounds · 15 vendors listed · 6 graded · audit of 2 Nov 2026 · prices checked 3 Nov 2026independent · grades can’t be bought

116 compounds · evidence graded A to F · prices per mg from in-stock offers

peptide and research product database

Search 116 research product identities by name, alias, market and form. Read source-reviewed notes and compare dated vendor packages.

every compound

research market · not for human use

These vendors sell compounds as research chemicals. Most are not FDA-approved.
Compounds with evidence grade, status, lowest and median price per mg
compoundevidenceUS statusfromlowest $/mgmedian $/mgvendorsassays per lot
GHK-Cu
copper tripeptide
rulemaking pending$39.99$0.40$0.7359×
Ipamorelin
ghrelin-receptor agonist
compounding restricted$49.99$5.00$6.0049×
NAD+
coenzyme
research only$74.99$0.06$0.1859×
Epithalon
pineal tetrapeptide
rulemaking pending$30.00$1.60$2.8039×
CJC-1295 (No DAC)
GHRH analogue
compounding restricted$39.47$6.50$8.0039×
Glutathione
antioxidant tripeptide
research only$119.99$0.08$0.1129×
DSIP
delta sleep-inducing peptide
compounding restricted$29.99$6.00$7.5059×
Selank
tuftsin analogue
research only$39.99$4.00$6.0059×
Semax
ACTH 4–10 analogue
rulemaking pending$34.99$2.50$5.2059×
Kisspeptin-10
hypothalamic peptide
investigational$59.99$6.00$6.00410×
Hexarelin
GH secretagogue
research only$44.99$9.00$9.0024×
GHRP-2
GH secretagogue
compounding restricted$34.99$3.50$4.0024×

12 of 116 compounds. Prices are listed prices before codes and shipping; per mg uses the package’s labelled amount. Evidence grades describe published human evidence, not product quality.

how the grades work

evidence grades

approved, strong human outcome data
phase 2–3 human trials, not yet approved
small or early human studies
animal or cell studies only
contradicted, unsafe, or identity problems

Graded on published human evidence by an editorial first pass that is awaiting expert review. Grades come from the literature; no vendor can pay for a grade or a ranking. editorial policy